Top View
- A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes
- Assessment Report – Sunosi
- Wakix, INN-Pitolisant Hydrochloride
- Wakefulness-Promoting Agents – Wakix® (Pitolisant Tablets)
- Structural Modifications and in Vitro Pharmacological Evaluation of 4
- Central Histaminergic Signaling, Neural Excitability and Epilepsy
- The European Histamine Research Society 48Th Annual Meeting, May 15–18Th, 2019 Krako´W, Poland
- Efficacy of Pitolisant on the Treatment of Narcolepsy: a Systematic Review
- Wakix (Pitolisant) Xyrem (Sodium Oxybate) Xywav
- (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor
- Pharmaabkommen A1 E
- Histamine H3 Receptor Antagonists/Inverse Agonists
- Substance Abuse in the Workplaces of Our Bodies and Mind
- Stimulants and Related Agents
- Therapeutic Class Review
- Effects of Pitolisant, a Histamine H3 Inverse Agonist, in Drug-Resistant
- Pitolisant Protects Mice Chronically Treated with Corticosterone From
- Orange Book Cumulative Supplement 7 July 2021
- Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy Laura Pérez-Carbonell, MD
- Wakix (Pitolisant) Annual Review Date: 09/17/2020
- Wakix Prior Authorization with Quantity Limit Program Summary
- Discovery of Potential, Dual-Active Histamine H3 Receptor Ligands with Combined Antioxidant Properties
- Pharmacogenomic Biomarkers and Their Applications in Psychiatry
- Long-Term Use of Pitolisant to Treat Patients With
- Wakix for Excessive Daytime Sleepiness
- Wakix® (Pitolisant)
- Lääkeluettelon Aineet, Liite 1
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- WAKIX (Pitolisant) RATIONALE for INCLUSION in PA PROGRAM
- Shared Care Guideline